The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Pacira BioSciences, Inc.

LOS ANGELES, CA / ACCESS Newswire / February 14, 2025

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before March 14, 2025.

Pacira BioSciences, Inc. is facing a class action lawsuit for allegedly violating securities laws during the specified Class Period. The lawsuit alleges that the Company made false and misleading statements regarding its business operations and financial performance, which ultimately led to financial harm for investors who purchased its securities during that time frame.

It is important for investors who may have been affected by these alleged violations to contact The Schall Law Firm before the deadline on March 14, 2025. The firm specializes in representing shareholders in securities litigation and is dedicated to protecting the rights of investors who have suffered losses due to corporate misconduct.

Investors should take action to ensure that their legal rights are protected and to seek potential compensation for any losses incurred as a result of the alleged violations by Pacira BioSciences, Inc. The outcome of this class action lawsuit could have significant implications for the Company and its shareholders.

How This Will Impact Me

As an investor who purchased Pacira BioSciences, Inc. securities during the specified Class Period, you may be eligible to participate in the class action lawsuit against the Company. By contacting The Schall Law Firm before the deadline on March 14, 2025, you can ensure that your legal rights are protected and potentially seek compensation for any financial losses you may have suffered.

How This Will Impact the World

The outcome of the class action lawsuit against Pacira BioSciences, Inc. could have broader implications for the world of securities litigation and corporate transparency. If the allegations of securities law violations are proven true, it could lead to increased scrutiny of other companies’ financial disclosures and potentially result in changes to regulatory oversight in the financial markets.

Conclusion

It is crucial for investors who purchased Pacira BioSciences, Inc. securities during the Class Period to take action and contact The Schall Law Firm before the deadline on March 14, 2025. By seeking legal representation and participating in the class action lawsuit, investors can protect their rights and potentially recover any losses incurred due to the alleged securities law violations by the Company.